{"commentary":{"count":19,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":11,"podcast":4,"x_thread":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02292758\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT02292758","nct_id":"NCT02292758","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct02292758. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Patients receive cetuximab IV over 90-120 minutes, bevacizumab IV over 30-90 minutes, and irinotecan IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.","label":"Arm I (cetuximab, bevacizumab, irinotecan)","type":"EXPERIMENTAL"},{"description":"Patients receive cetuximab IV over 90-120 minutes, placebo IV over 30-90 minutes, and irinotecan IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.","label":"Arm II (cetuximab, placebo, irinotecan)","type":"ACTIVE_COMPARATOR"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2019-09-27","type":"ACTUAL"},"conditions":["Colorectal Adenocarcinoma","RAS Wild Type","Stage IV Colorectal Cancer AJCC v7","Stage IVA Colorectal Cancer AJCC v7","Stage IVB Colorectal Cancer AJCC v7"],"enrollment":{"count":36,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Bevacizumab","type":"BIOLOGICAL"},{"name":"Cetuximab","type":"BIOLOGICAL"},{"name":"Irinotecan","type":"DRUG"},{"name":"Laboratory Biomarker Analysis","type":"OTHER"},{"name":"Placebo","type":"OTHER"}],"last_update":"2022-01-31","lead_sponsor":"Academic and Community Cancer Research United","official_title":"BOND-3: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in RAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2019-03-20","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS)","timeFrame":"From the date of randomization to the date of 1st documented disease progression or death due to any cause, whichever occurs first, assessed up to 24 months"},{"measure":"6-month and 12-month Progression-free Survival (PFS) Rates","timeFrame":"From the date of randomization to the date of 1st documented disease progression or death due to any cause, whichever occurs first, assessed up to 24 months"}],"references":[{"citation":"Lipsyc-Sharf M, Ou FS, Yurgelun MB, Rubinson DA, Schrag D, Dakhil SR, Stella PJ, Weckstein DJ, Wender DB, Faggen M, Zemla TJ, Heying EN, Schuetz SR, Noble S, Meyerhardt JA, Bekaii-Saab T, Fuchs CS, Ng K. Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial. Oncologist. 2022 Apr 5;27(4):292-298. doi: 10.1093/oncolo/oyab025.","pmid":"35380713","type":"DERIVED"}],"start_date":{"date":"2014-12-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery","url":"https://clinicaltrials.gov/study/NCT02292758"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct02292758"}